New study tracks how melanoma patients use a smartphone app during targeted treatment
NCT ID NCT04911998
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study followed about 400 adults with advanced BRAF-mutant melanoma who were taking targeted therapy (BRAF/MEK inhibitors) and using a smartphone app called TavieSkin. The goal was to describe patient characteristics, how they used the app, their quality of life, and treatment satisfaction. No new treatments were given; researchers simply collected data from app users across several European countries.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAF V600 MUTATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hospital Evora
Evora, Portugal
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a One-Two punch of immune boosters revive cancer treatment?
- Could a personal coach at home boost energy for cancer patients?
- Morning vs. afternoon: could the clock boost immunotherapy against melanoma?
- Could a common vaccine supercharge immunotherapy against melanoma?
- Astrophysics meets dermatology: AI that maps moles like stars to catch melanoma early
- Engineered immune cells take aim at Hard-to-Treat cancers